Nordamnacanthal potentiates the cytotoxic effects of tamoxifen in human breast cancer cells

Oncology Letters

Volumn 9, Issue 1, 2015, Pages 335-340

  Subramani, Tamilselvan ^a   Yeap, Swee Keong ^b   Ho, Wan Yang ^c   Ho, Chai Ling ^a   Osman, Che Puteh ^d   Ismail, Nor Hadiani ^d   Rahman, Nik Mohd Afizan Nik Abdul ^a   Alitheen, Noorjahan Banu ^a  

^a Department of Cell and Molecular Biology ^*  (Malaysia)

^b UNIVERSITY PUTRA MALAYSIA   (Malaysia)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^d UNIVERSITI TEKNOLOGI MARA   (Malaysia)

Author keywords

Apoptosis; Breast cancer; Combination treatment; MCF 7; Nordamnacanthal; Tamoxifen

Indexed keywords

ANTHRAQUINONE DERIVATIVE; LIPOCORTIN 5; NORDAMNACANTHAL; REACTIVE OXYGEN METABOLITE; TAMOXIFEN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CANCER; CELL CYCLE ASSAY; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LIPID PEROXIDATION; MITOCHONDRIAL MEMBRANE POTENTIAL; MTT ASSAY;

EID: 84911416710     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.2697     Document Type: Article

References (24)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2009. CA Cancer J Clin 59: 225-249, 2009.
2. Goldhirsch A, Ingle JN, Gelber RD, et al: Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 20: 1319-1329, 2009.
3. Radmacher MD and Simon R: Estimation of tamoxifen's efficacy for preventing the formation and growth of breast tumors. J Natl Cancer Inst 92: 48-53, 2000.
4. Early Breast Cancers Trialists' collaborative group: Tamoxifen for an early breast cancer: an overview of the randomised trials. Lancet 351: 1451-1467, 1998.
5. Love RR: Tamoxifen therapy in primary breast cancer: biology, efficacy, and side effects. J Clin Oncol 7: 803-815, 1989.
6. Marshall E: Tamoxifen: ‘a big deal,’ but a complex hand to play. Science 280: 196, 1998.
7. Parvez S, Tabassum H, Rehman H, et al: Catechin prevents tamoxifen-induced oxidative stress and biochemical perturbations in mice. Toxicology 225: 109-118, 2006.
8. Conklin KA: Chemotherapy-associated oxidative stress: impact on chemotherapeutic effectiveness. Integr Cancer Ther 3: 294-300, 2004.
9. Fisher B, Constantino JP, Wickerham CD, et al: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90: 1371-1388, 1998.
10. Fornander T, Rutqvist LE, Cedermark B, et al: Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1: 117-120, 1989.
11. Johnston SR, Dowsett M and Smith IE: Towards a molecular basis for tamoxifen resistance in breast cancer. Ann Oncol 3: 503-511, 1992.
12. Osborne CK: Tamoxifen in the treatment of breast cancer. N Engl J Med 339: 1609-1618, 1998.
13. Ismail NH, Ali AM, Aimi N, et al: Anthraquinones from Morinda elliptica. Phytochemistry 45: 1723-1725, 1997.
14. Yazan LS, Ishak N and Lajis NH: BCL-2 was downregulated in G2/M-arrest breast cancer cells MCF-7-treated with Nordamnacanthal. J Pharm Sci & Res 2: 197-207, 2010.
15. Jasril, Lajis NH, Mooi LY, Abdullah MA, Sukari MA and Ali AM: Antitumor promoting and antioxidant activities of anthraquinones isolated from cell suspension culture of Morinda elliptica. Asia Pac J Mol Biol. Biotechnol 11: 3-7, 2003.
16. Kamiya K, Hamabe W, Tokuyama S, et al: Inhibitory effect of anthraquinones isolated from the noni (Morinda citrifolia) root on animal A-, B-, and Y-families of DNA polymerases and human cancer cell proliferation. Food Chem 118: 725-730, 2009.
17. Frank J, Kelleher DK, Pompella A, et al: Enhancement of oxidative cell injury and antitumor effects of localized 44 degrees C hyperthermia upon combination with respiratory hyperoxia and xanthine oxidase. Cancer Res 58: 2693-2698, 1998.
18. Jentzsch AM, Bachmann H, Furst P and Biesalski HK: Improved analysis of malondialdehyde in human body fluids. Free Radic Biol Med 20: 251-256, 1996.
19. Johnston SR: Acquired tamoxifen resistance in human breast cancer - potential mechanisms and clinical implications. Anticancer Drugs 8: 911-930, 1997.
20. Danova M, Pellicciari C, Zibera C, et al: Cell cycle kinetic effects of tamoxifen on human breast cancer cells. Flow cytometric analyses of DNA content, BrdU labeling, Ki-67, PCNA, and statin expression. Ann NY Acad Sci 698: 174-181, 1993.
21. Osborne CK, Boldt DH, Clark GM and Trent JM: Effects of tamoxifen on human breast cancer cell cycle kinetics: accumulation of cells in early G1 phase. Cancer Res 43: 3583-3585, 1983.
22. Li S, Zhou Y, Wang R, et al: Selenium sensitizes MCF-7 breast cancer cells to doxorubicin-induced apoptosis through modulation of phospho-Akt and its downstream substrates. Mol Cancer Ther 6: 1031-1038, 2007.
23. Li Z, Carrier L and Rowan BG: Methylseleninic acid synergizes with tamoxifen to induce caspase-mediated apoptosis in breast cancer cells. Mol Cancer Ther 7: 3056-3063, 2008.
24. Green DR and Reed JC: Mitochondria and apoptosis. Science 281: 1309-1312, 1998.